GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Retained Earnings

Oncodesign Precision Medicine (XPAR:ALOPM) Retained Earnings : €-15.53 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oncodesign Precision Medicine's retained earnings for the quarter that ended in Dec. 2024 was €-15.53 Mil.

Oncodesign Precision Medicine's quarterly retained earnings increased from Dec. 2023 (€-8.32 Mil) to Jun. 2024 (€0.00 Mil) but then declined from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€-15.53 Mil).

Oncodesign Precision Medicine's annual retained earnings declined from Dec. 2022 (€-0.23 Mil) to Dec. 2023 (€-8.32 Mil) and declined from Dec. 2023 (€-8.32 Mil) to Dec. 2024 (€-15.53 Mil).


Oncodesign Precision Medicine Retained Earnings Historical Data

The historical data trend for Oncodesign Precision Medicine's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Retained Earnings Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
-0.15 -2.94 -0.23 -8.32 -15.53

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial -0.23 -3.94 -8.32 - -15.53

Oncodesign Precision Medicine Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Oncodesign Precision Medicine  (XPAR:ALOPM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines